Keros Therapeutics: The Biology-First Bet on TGF-Beta Superfamily - $KROS

Dive into the high-stakes, rollercoaster world of clinical-stage biotech through the captivating story of Keros Therapeutics. Founded by a visionary scientist who walked away from a multi-billion-dollar success to build a "better engine" for targeting the body's complex TGF-beta master switches, Keros embodies the extreme risks and profound rewards of modern drug development. In just a few years, the company has weathered a pandemic-era IPO boom, celebrated breakthrough clinical data, secured a massive global partnership with Takeda, and survived a devastating pipeline failure that slashed its workforce and forced a dramatic strategic pivot. With the company's future now hinging on a pivotal Phase 3 trial for a potentially life-changing blood disorder therapy, this deep dive explores the underlying molecular science, the boardroom dealmaking, and the very real human lives hanging in the balance—offering a gripping look at what it truly takes to bring a next-generation medicine to the world.---Subscribe to our newsletter on LinkedIn https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7408775804387491842Follow us on X @emportop---Transcript - https://empor.top/us/KROSI. Introduction and Episode RoadmapII. The Scientific Foundation: Why TGF-Beta MattersIII. Founding Story and the Pontifax Connection (2015-2017)IV. Building the Pipeline: The Platform Strategy (2017-2019)V. The IPO and Going Public (April 2020)VI. Clinical Inflection Point No. 1: KER-050 Phase 2 Data (2021-2022)VII. Clinical Inflection Point No. 2: Expanding to Myelofibrosis (2022-2024)VIII. The Licensing Deals: From Hansoh to Takeda (2021-2025)IX. The Cibotercept Crisis and Corporate Restructuring (2024-2025)X. KER-065, the Pivot to Neuromuscular Disease, and the Phase 3 in MDS (2024-2026)XI. The Competitive Landscape and Strategic PositioningXII. Company Culture and Execution PlaybookXIII. Porter's Five Forces and Hamilton's 7 Powers AnalysisXIV. Bull vs. Bear CaseXV. The Narrative Arc and LessonsXVI. Epilogue: The Next ChapterXVII. Further Reading